Detailed Mechanism Funding and Narrative

Years of mechanism: 2013 2014 2015 2016 2017

Details for Mechanism ID: 16749
Country/Region: Ethiopia
Year: 2016
Main Partner: Columbia University
Main Partner Program: NA
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $12,226,721 Additional Pipeline Funding: $2,475,000

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $851,105
Care: TB/HIV (HVTB) $477,482
Care: Pediatric Care and Support (PDCS) $167,131
Laboratory Infrastructure (HLAB) $46,812
Strategic Information (HVSI) $40,969
Health Systems Strengthening (OHSS) $138,971
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $109,810
Biomedical Prevention: Blood Safety (HMBL) $21,320
Testing: HIV Testing and Counseling (HVCT) $93,737
Sexual Prevention: Other Sexual Prevention (HVOP) $25,314
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $77,333
Treatment: Adult Treatment (HTXS) $9,495,584
Treatment: Pediatric Treatment (PDTX) $681,153
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 121
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 94
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 129
GEND_GBV Number of people receiving post-GBV care 2017 218
HRH_PRE By Graduates: Doctors 2017 973
HRH_PRE By Graduates: Other 2017 59
HRH_PRE Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre 2017 1,032
HRH_PRE Sum of Graduates disaggregates 2017 1,032
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 44,710
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 46,405
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 241,713
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 178,495
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 511,323
HTS_TST Service Delivery Point (Facility): Inpatient 2017 52,132
HTS_TST Service Delivery Point (Facility): Other PITC 2017 34,743
HTS_TST Service Delivery Point (Facility): Outpatient 2017 199,841
HTS_TST Service Delivery Point (Facility): PMTCT 2017 76,890
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 39,103
HTS_TST Service Delivery Point (Facility): VCT 2017 108,614
HTS_TST Sum of Aggregated Age/Sex <15 2017 91,115
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 420,208
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 511,323
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 184
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 211
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 2,231
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 934
LAB_PT CD4: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 11
LAB_PT CD4: Number of laboratories that participate in this PT program 2017 11
LAB_PT CD4: Number of laboratories that perform this testing 2017 32
LAB_PT Early infant diagnostics: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that participate in this PT program 2017 1
LAB_PT Early infant diagnostics: Number of laboratories that perform this testing 2017 1
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 59
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that participate in this PT program 2017 59
LAB_PT HIV serologic/diagnostic testing: Number of laboratories that perform this testing 2017 59
LAB_PT HIV viral load: Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that participate in this PT program 2017 1
LAB_PT HIV viral load: Number of laboratories that perform this testing 2017 1
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that achieve acceptable successful passing criteria in this PT program 2017 21
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that participate in this PT program 2017 21
LAB_PT TB diagnostics (AFB microscopy): Number of laboratories that perform this testing 2017 59
LAB_PT TB diagnostics (Xpert MTB/RIF): Number of laboratories that perform this testing 2017 7
PMTCT_ART Already on ART at beginning of current pregnancy 2017 955
PMTCT_ART New on ART 2017 457
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 70,077
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 1,005
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 251
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 12
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 21
PMTCT_EID Sum of Infant Age disaggregates 2017 1,256
PMTCT_STAT By: Known positives at entry 2017 995
PMTCT_STAT By: Number of new positives identified 2017 511
PMTCT_STAT Number of new ANC and L&D clients 2017 73,850
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 70,077
PMTCT_STAT Sum of Positives Status disaggregates 2017 1,506
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2017 3,178
PP_PREV Total number of people in the target population 2017 3,812
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 22
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 170
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 31
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 230
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 453
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 453
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 1,201
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 1
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 3
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 4
TB_SCREENDX Screen Result: Screened Positive for TB 2017 1,712
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 9,740
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 5,968
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 617
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 740
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 17,065
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 208
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,301
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 275
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,640
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 3,424
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 3,516
TX_CURR Aggregated Age/Sex: <15 Female 2017 653
TX_CURR Aggregated Age/Sex: <15 Male 2017 791
TX_CURR Aggregated Age/Sex: 15+ Female 2017 10,882
TX_CURR Aggregated Age/Sex: 15+ Male 2017 6,678
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 18,985
TX_CURR Sum of Aggregated Age/Sex <15 2017 1,444
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 17,560
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 19,004
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 207
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 239
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 1,901
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 1,054
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 3,424
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 3,401
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 12,327
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 9,859
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 363
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 431
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 5,632
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 3,433
TX_PVLS Numerator: Indication: Routine 2017 7,888
TX_PVLS Numerator: Indication: Targeted 2017 1,971
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 447
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 540
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 7,041
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 4,299
TX_PVLS_den Denominator: Indication: Routine 2017 9,860
TX_PVLS_den Denominator: Indication: Targeted 2017 2,467
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 3
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 128
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 155
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 37
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,506
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 21
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 825
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 71
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 2,614
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 76
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 2,917
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 4
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 147
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 5
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 175
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 44
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,679
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 23
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 916
VMMC_CIRC By Age: 10-14 2017 6,524
VMMC_CIRC By Age: 15-19 2017 816
VMMC_CIRC By Age: 20-24 2017 397
VMMC_CIRC By Age: 25-29 2017 255
VMMC_CIRC By Age: 30-49 2017 3,321
VMMC_CIRC By Age: 50+ 2017 1,971
VMMC_CIRC By circumcision technique: Surgical VMMC 2017 13,284
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 13,284
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2017 13,284
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2017 9,708
Cross Cutting Budget Categories and Known Amounts Total: $284,526
Human Resources for Health $138,971
Food and Nutrition: Policy, Tools, and Service Delivery $45,555
Gender: Gender Based Violence (GBV) $100,000
GBV Prevention
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation
Post GBV Care
Collection and Use of Gender-related Strategic Information
Implementation
Capacity building
Monitoring and Evaluation